Latest News and Press Releases

Reference is made to the stock exchange notice of 10 February 2017 regarding the board of directors' resolution to increase the share capital in Targovax ASA (the "Company") in connection with the...

Reference is made to the stock exchange notice of 10 February 2017 regarding increase of the share capital in Targovax ASA (the "Company") relating to exercise of employee options and settlement of...

Oslo, Norway, 16 February 2017 - Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces...

Lars Lund-Roland, board member of Targovax ASA, has on 13 February 2017 subscribed 4,417 shares in Targovax ASA at a price of NOK 0.10 per share in connection with settlement of vested restricted...

The board of directors of Targovax ASA (the "Company"), has on 9 February 2017, in accordance with the authorisations granted by the general meeting 13 April 2016, resolved: to increase the share...

Oslo, Norway, 6 February 2017 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, will announce its fourth quarter and full...

Survival rate of 68% from first patient cohort vs published historical rate of 30-53% suggests signal of clinical efficacy for the drug candidate  Full data set from first patient cohort to be...

Oslo, Norway, 5 January 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that...

Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target, primarily, treatment-resistant solid tumors, announces that...

Oslo, Norway, 9 December 2016: The Board of Directors of Targovax ASA (the "Company") has resolved to grant 420,000 options to subscribe for shares in the Company to employees under the Company's...